Seelos Therapeutics Inc (SEEL)’s stock has witnessed a price declined of -1.19% from the previous close with its current price standing at $0.12. Its current price is -92.47% under its 52-week high of $1.66 and 17.37% more than its 52-week low of $0.11. Based on the past 30-day period, the stock price is -44.52% below the high and +15.12% above the low.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, SEEL’s SMA-200 is $0.8011.
Additionally, it is important to take into account SEEL stock ratios, including its price-to-sales ratio, which is 13.01 for the last tewlve months.
How does Seelos Therapeutics Inc (SEEL) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 3 brokerage firms that recommend the stock as a Moderate Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 4.33 in simple terms.
Seelos Therapeutics Inc (SEEL): Earnings History
If we examine Seelos Therapeutics Inc’s recent earnings history, in the last quarter ended on 9/29/2023, it posted adjusted earnings per share of -$0.12, beating the consensus of -$0.06. In other words, it beat the consensus by -$0.06, resulting in a -100.00% surprise. In the 3 months period before the previous quarter which was closed on 9/29/2023, the stock recorded adjusted earnings per share of -$0.12 in contrast with the Outlook of -$0.06. That was a difference of -$0.06 and a surprise of -100.00%.
Seelos Therapeutics Inc (NASDAQ: SEEL) Ownership Details
I will give a breakdown of the key shareholders in Seelos Therapeutics Inc (SEEL). Recent figures show that the company’s insiders hold 2.81% of shares. A total of 93 institutional investors hold shares in the company, making 20.36% of its stock and 20.95% of its float.
Jun 29, 2023, it was reported that the Company’s largest institutional holder is Gendell, Jeffrey L. holding total of 5.17 million shares that make 4.04% of the company’s total number of shares and are currently priced at 6.18 million.
The securities firm Vanguard Group Inc holds 5.0 million shares of SEEL, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 3.91%, and the holding percentage of shares is valued at 5.97 million.
An overview of Seelos Therapeutics Inc’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Seelos Therapeutics Inc (SEEL) traded 3,604,186 shares per day, with a moving average of $0.1653 and price change of -0.0850. With the moving average of $0.2696 and a price change of -0.8874, about 6,674,842 shares changed hands on average over the past 50 days. Finally, SEEL’s 100-day average volume is 3,795,046 shares, alongside a moving average of $0.7788 and a price change of -1.0874.